Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis

Gut

Volumn 40, Issue 6, 1997, Pages 798-800

  Mahmoud, A E A ^a   Elias, E ^a   Beauchamp, N ^c   Wilde, J T ^b  

^a Liver and Hepatobiliary Unit

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Factor V Leiden; Hepatic vein; Portal vein; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; HEPATIC VEIN; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCOAGULABILITY; LIVER VEIN THROMBOSIS; MALE; POLYMERASE CHAIN REACTION; PORTAL VEIN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THROMBOPHILIA; THROMBOSIS;

EID: 0030834237     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.6.798     Document Type: Article

References (25)

1. Boughton BJ. Hepatic and portal vein thrombosis closely associated with chronic myeloproliferative disorders. BMJ 1901; 302: 192-3.
2. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. Ann Intern Med 1985; 103: 329-34.
3. Mitchell MC, Boitnott JK, Kaufman S, Cameron JL, Maddrey WC. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine 1982; 61: 199-218.
4. Mahmoud AEA, Mendoza A, Meshikhes AN, Olliff S, West R, Neuberger J, et al. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. Q J Med 1996; 89: 37-43.
5. Pelletier S, Landi B, Piette JC, Ekert P, Coutellier A, Desmoulins C, et al. Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome. J Hepatol 1994; 21: 76 80.
6. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou J-P. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. Gastroenterology 1986; 90: 807-11.
7. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-9.
8. Valla D, Denninger M-H, Delvigne J-M, Rueff B, Benhamou J-P. Portal vein thrombosis with ruptured oesophageal varices as presenting manifestation of hereditary protein C deficiency. Gut 1988; 29: 856-9.
9. Sas G, Blasko G , Petr I, Griffin JH. A protein S deficient family with portal vein thrombosis. Thromb Haemost 1985; 54: 724.
10. Prat F, Ouzan D, Trecziak N, Trepo C. Portal and mesenteric thrombosis revealing constitutional protein C deficiency. Gut 1989; 30: 416.
11. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
12. Bertina RM, Koeleman PC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64 7.
13. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
14. Mahmoud AEA, Wilde JT, Elias H. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995; 345: 526.
15. Denninger M-H, Beldjord K, Durand F, Denié C, Valla D, Guillin M-C. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995, 345: 525-6.
16. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-23.
17. Rosendaal FR, Koster T, Vaandenbrouke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
18. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-17.
19. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
20. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased incidence of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
21. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
22. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protien C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-5.
23. Zoller B, Bemtsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
24. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
25. Belli L, Sansalone CV, Aseni P, Romani F, Rondinara G. Portal thrombosis in cirrhotics. A retrospective analysis. Ann Surg 1986; 203: 286-91.